GSK's AREXVY Vaccine Receives Expanded Approval In Canada For Adults Aged 50-59 At Increased Risk Of RSV, Offering Enhanced Protection Ahead Of Peak Season; Clinical Trials Ongoing For Adults 18-49
GSK's AREXVY Vaccine Receives Expanded Approval In Canada For Adults Aged 50-59 At Increased Risk Of RSV, Offering Enhanced Protection Ahead Of Peak Season; Clinical Trials Ongoing For Adults 18-49
葛蘭素史克的AREXVY生物-疫苗獲得加拿大擴展批准，面向50-59歲增加RSV風險的成年人，提供在高峰季節前增強保護；18-49歲成年人的臨床試驗正在進行中
GSK's AREXVY Vaccine Receives Expanded Approval In Canada For Adults Aged 50-59 At Increased Risk Of RSV, Offering Enhanced Protection Ahead Of Peak Season; Clinical Trials Ongoing For Adults 18-49
葛蘭素史克的AREXVY生物-疫苗獲得加拿大擴展批准，面向50-59歲增加RSV風險的成年人，提供在高峰季節前增強保護；18-49歲成年人的臨床試驗正在進行中
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間